BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...

The Units may be offered for sale to prospective investors (each, an “Investor”) (i) in all provinces and territories of Canada pursuant to available prospectus exemptions, (ii) in the United States ...

BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological ...

The company plans to use the proceeds to support exploration at the Lunahuasi project in Argentina and the Los Helados ...

XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical ...

The Private Placement remains subject to market conditions ... to the public of the securities requiring publication of a prospectus in any relevant Member State, including France and Germany.

Bioscience Corp. (Nasdaq:LEXX; LEXXW), a developer of drug delivery platforms, today announced that it has closed a ...

The offering is being made only by means of a prospectus which is a part of the effective registration statement. The warrants will be issued in a concurrent private placement. A final prospectus ...

KBC Securities NV, Belfius Bank NV/SA in cooperation with Kepler Cheuvreux SA, and Coöperatieve Rabobank U.A. acted as Joint Global Coordinators of the private placement ... pursuant to an exemption ...

In connection with the Private Placement, the Company ... offer to the public of the securities requiring publication of a prospectus in any relevant Member State, including France and Germany.